The efficacy of pirfenidone in a sheep model of pulmonary fibrosis
Autor: | Emmanuel Koumoundouros, Louise Organ, Kopiyawaththage U. E. Perera, Kenneth J. Snibson, Habtamu B Derseh, Chrishan S. Samuel, Andrew Stent, Sasika N. Vithana Dewage |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Indoles Pyridones medicine.medical_treatment Clinical Biochemistry Pharmacology Bleomycin 03 medical and health sciences chemistry.chemical_compound Idiopathic pulmonary fibrosis 0302 clinical medicine Fibrosis Pulmonary fibrosis medicine Animals Myofibroblasts Molecular Biology Saline Lung Sheep business.industry Pirfenidone respiratory system medicine.disease Idiopathic Pulmonary Fibrosis respiratory tract diseases Extracellular Matrix Disease Models Animal 030104 developmental biology medicine.anatomical_structure 030228 respiratory system chemistry Nintedanib Female business medicine.drug |
Zdroj: | Experimental lung research. 45(9-10) |
ISSN: | 1521-0499 |
Popis: | Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with unknown cause. While the drugs nintedanib and pirfenidone have been approved for the treatment of IPF, they only slow disease progression and can induce several side-effects, suggesting that there is still an unmet need to develop new efficacious drugs, and interventions strategies, to combat this disease. We have recently developed a sheep model of pulmonary fibrosis for the preclinical testing of novel anti-fibrotic drugs. The aim of this study was to assess the effects of pirfenidone to ascertain its suitability as a benchmark for comparing other novel therapeutics in this sheep model. To initiate localized fibrosis, sheep were given two infusions of bleomycin (0.6 U/ml per infusion), a fortnight apart, to a specific lung segment. The contralateral lung segment in each sheep was infused with saline to act as an internal control. Two weeks after the final bleomycin infusion, either pirfenidone or methylcellulose (vehicle control) were administered orally to sheep twice daily for 5 weeks. Results showed that sheep treated with pirfenidone had improved lung function, ameliorated fibrotic pathology, lower numbers of active myofibroblasts, and reduced extra cellular matrix deposition when compared with the relevant measurements obtained from control sheep treated with vehicle. This study showed that pirfenidone can attenuate bleomycin-induced pulmonary fibrosis in sheep, and can therefore be used as a positive control to assess other novel therapeutics for IPF in this model. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |